{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:11:44Z","timestamp":1781021504166,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1038\/pcan.2013.35","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T10:15:17Z","timestamp":1380622517000},"page":"382-386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients"],"prefix":"10.1038","volume":"16","author":[{"given":"L A","family":"Kachnic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S L","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A B","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-G","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H E","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Nabid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C A F","family":"Lawton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,1]]},"reference":[{"key":"BFpcan201335_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0360-3016(00)01516-9","volume":"49","author":"CA Lawton","year":"2001","unstructured":"Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937\u2013946.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFpcan201335_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.urology.2005.07.017","volume":"67","author":"JM Bruder","year":"2006","unstructured":"Bruder JM, Ma JZ, Basler JW, Welch MD . Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 2006; 67: 152\u2013155.","journal-title":"Urology"},{"key":"BFpcan201335_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/cncr.20388","volume":"101","author":"TL Krupski","year":"2004","unstructured":"Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004; 101: 541\u2013549.","journal-title":"Cancer"},{"key":"BFpcan201335_CR4","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"MR Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008\u20132012.","journal-title":"J Urol"},{"key":"BFpcan201335_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0021-9681(74)90015-0","volume":"27","author":"M Zelen","year":"1974","unstructured":"Zelen M . The randomization and stratification of patients to clinical trials. J Chronic Dis 1974; 27: 365\u2013375.","journal-title":"J Chronic Dis"},{"key":"BFpcan201335_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570\u2013579.","journal-title":"J Clin Oncol"},{"key":"BFpcan201335_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/pcan.2011.4","volume":"15","author":"A Serpa Neto","year":"2012","unstructured":"Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2012; 15: 36\u201344.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201335_CR8","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1111\/j.1464-410X.2010.09329.x","volume":"106","author":"P Taxel","year":"2010","unstructured":"Taxel P, Dowsett R, Richter L, Fall P, Klepinger A, Albertsen P . Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int 2010; 106: 1473\u20131476.","journal-title":"BJU Int"},{"key":"BFpcan201335_CR9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Nelson JB, Trump DL, Resnick NM . Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416\u2013424.","journal-title":"Ann Intern Med"},{"key":"BFpcan201335_CR10","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/cncr.20056","volume":"100","author":"TH Diamond","year":"2004","unstructured":"Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR . Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004; 100: 892\u2013899.","journal-title":"Cancer"},{"key":"BFpcan201335_CR11","unstructured":"National Osteoporosis Foundation. Clinician\u2019s guide to prevention and treatment of osteoporosis Washington, DC: National Osteoporosis Foundation, 2008."},{"key":"BFpcan201335_CR12","doi-asserted-by":"publisher","first-page":"680","DOI":"10.7326\/0003-4819-148-9-200805060-00008","volume":"148","author":"A Qaseem","year":"2008","unstructured":"Qaseem A, Snow V, Shekelle P, Hopkins R Jr., Forciea MA, Owens DK . Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 148: 680\u2013684.","journal-title":"Ann Intern Med"},{"key":"BFpcan201335_CR13","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A . Case finding for the management of osteoporosis with FRAX\u2014assessment and intervention thresholds for the UK. Osteoporos Int 2008; 19: 1395\u20131408.","journal-title":"Osteoporos Int"},{"key":"BFpcan201335_CR14","first-page":"S1","volume":"167","author":"JP Brown","year":"2002","unstructured":"Brown JP, Josse RG 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167, (10 Suppl): S1\u201334.","journal-title":"CMAJ"},{"key":"BFpcan201335_CR15","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1001\/jama.299.12.1468","volume":"299","author":"AM Cheung","year":"2008","unstructured":"Cheung AM, Detsky AS . Osteoporosis and fractures: missing the bridge? JAMA 2008; 299: 1468\u20131470.","journal-title":"JAMA"},{"key":"BFpcan201335_CR16","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1503\/cmaj.100771","volume":"182","author":"A Papaioannou","year":"2010","unstructured":"Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S et al2010 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182: 1864\u20131873.","journal-title":"CMAJ"},{"key":"BFpcan201335_CR17","unstructured":"World Health Organization. FRAX WHO Fracture Risk Assessment Tool World Health Organization, 2012; Available at: www.shef.ac.uk\/FRAX\/. . Accessed 6 October 2013."},{"key":"BFpcan201335_CR18","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/j.juro.2010.02.022","volume":"183","author":"PJ Saylor","year":"2010","unstructured":"Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR . Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 2010; 183: 2200\u20132205.","journal-title":"J Urol"},{"key":"BFpcan201335_CR19","unstructured":"Osteoporosis Canada. Available at www.osteoporosis.ca. last. Accessed September 2012."},{"key":"BFpcan201335_CR20","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","volume":"367","author":"S Boonen","year":"2012","unstructured":"Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012; 367: 1714\u20131723.","journal-title":"N Engl J Med"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201335","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:34:20Z","timestamp":1648676060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["BFpcan201335"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2013.35","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,1]]},"assertion":[{"value":"13 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}